Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00368550 · ClinicalTrials.gov registry record · Phase 4
Sertraline Pharmacotherapy for Alcoholism Subtypes
A Phase 4 study of Alcoholism, sponsored by UConn Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 134
- Enrollment target
- 1
- Study location
NCT00368550: Completed Phase 4 study of Alcoholism, sponsored by UConn Health.
NCT00368550 is a Phase 4 study of Alcoholism that has completed, run by UConn Health. The registered enrollment target is 134 participants, below the 373-participant average among 65 other Alcoholism trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00368550, a Phase 4 study of Alcoholism, has completed, sponsored by UConn Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 134 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether Sertraline, compared to placebo, is effective in the treatment of alcohol dependence as a function of the subtype of alcoholic patient being treated. This involved administering sertraline (to a maximum of 200 mg/day) or an inactive placebo for a 14-week treatment period.
Primary Outcome
Obtained using daily interactive voice response data augmented by Timeline Followback data. Missing days were treated as drinking days.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Sertraline
Study Locations (1)
Connecticut
- University of Connecticut Health Center - Farmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2004-02 |
| Est. Completion | 2009-12 |
| Phase | Phase 4 |
What the finished NCT00368550 record still lists
NCT00368550 is an interventional study that assigns participants to a tested intervention. The registered 134 participants enrollment target is mid-sized for trials with a published cap, below the 373-participant average among 65 other Alcoholism trials with a reported enrollment target (64% lower).
The record links to 1 condition, with Alcoholism appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00368550 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT00368550 about?
NCT00368550 is a clinical study titled "Sertraline Pharmacotherapy for Alcoholism Subtypes". The purpose of this study is to determine whether Sertraline, compared to placebo, is effective in the treatment of alcohol dependence as a function of the subtype of alcoholic patient being treated. This involved administering sertraline (to a maximum of 200 mg/day) or an inactive placebo for a 14-...
What is the current status of trial NCT00368550?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 134 participants. The study started on 2004-02. Estimated completion is 2009-12.
What conditions does trial NCT00368550 study?
This clinical trial studies the following conditions: Alcoholism.
What interventions are being tested in trial NCT00368550?
The interventions under investigation include: Placebo (DRUG), Sertraline (DRUG).
Who is sponsoring clinical trial NCT00368550?
This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00368550 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcoholism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00368550's enrollment target sits among peer trials
134 31st of 65 higher than 35 of 65 other Alcoholism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcoholism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Naltrexone in AUD Reward Drinkers
RECRUITING · Phase 4
-
Naltrexone Treatment of Alcohol Abuse in Schizophrenia
COMPLETED · Phase 4
-
Naltrexone, Craving, and Drinking
COMPLETED · Phase 4
-
Naltrexone for Heavy Drinking in Young Adults
COMPLETED · Phase 4
-
Managing Alcoholism in People Who Do Not Respond to Naltrexone
COMPLETED · Phase 4
-
Drug Treatment for Depressed Alcoholics (Naltrexone/Fluoxetine)
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02469662 · 134 participants · NA
Clinical Outcomes Study of the Nexel Total Elbow
- NCT03110822 · 134 participants · Phase 1
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
- NCT04678648 · 134 participants · Phase 1
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
- NCT05264857 · 134 participants · NA
Decision Aid and Thyroid Nodules Management
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia